490 BioTech receives NIH Phase II SBIR award for improving drug discovery screens and 3D microphysiological assays

490 BioTech is pleased to announce the acquisition of a Phase II SBIR award from the National Institutes of Health, National Institute of General Medical Sciences for the development of new high-throughput drug discovery screens that are more predictive of pharmacological safety and toxicity. Using our autobioluminescent expression system, we will create novel data-intensive, autonomous, multi-organ screening assays that are more complementary toward the needs of emerging three-dimensional microphysiological ‘organ-on-chip’ and microtiter plate-based culture systems.